Abstract
Here we report methods of preparation for liposome formulations containing lipophilic drugs. In contrast to the encapsulation of water soluble compounds into the entrapped aqueous volume of a liposome, drugs with lipophilic properties are incorporated into the phospholipid bilayer membrane. Water-soluble molecules, for example cytotoxic or antiviral nucleosides can be transformed into lipophilic compounds by attachment of long alkyl chains, allowing their stable incorporation into liposome membranes and taking advantage of the high loading capacity lipid bilayers provide for lipophilic molecules. We created a new class of cytotoxic drugs by chemical transformation of the hydrophilic drugs cytosine-arabinoside (ara-C), 5-fluoro-deoxyuridine (5-FdU), and ethinylcytidine (ETC) into lipophilic compounds and their formulation in liposomes.
The concept of chemical modification of water-soluble molecules by attachment of long alkyl chains and their stable incorporation into liposome bilayer membranes represent a very promising method for the development of new drugs not only for the treatment of tumors or infections but also for many other diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16:691–707
Perez-Lopez ME, Curiel T, Gomez JG, Jorge M (2007) Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18:611–617
Porter CA, Rifkin RM (2007) Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma S4:S150–S155
Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H (2006) Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106:120–127
Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 17:735–749
Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201–230
Fahr A, Liu X (2007) Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 4:403–416
ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665–685
Brusa P, Immordino ML, Rocco F, Cattel L (2007) Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res 27:195–199
Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad O, Breistol K, Peters GJ (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides Nucleotides Nucleic Acids 23:1329–1333
Stevens PJ, Sekido M, Lee RJ (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 21:2153–2157
Pignatello R, Puleo A, Puglisi G, Vicari L, Messina A (2003) Effect of liposomal delivery on in vitro antitumor activity of lipophilic conjugates of methotrexate with lipoamino acids. Drug Deliv 10:95–100
Zerouga M, Stillwell W, Jenski LJ (2002) Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid and methotrexate that inhibits cell proliferation. Anticancer Drugs 13:301–311
Harrington KJ, Syrigos KN, Uster PS, Zetter A, Lewanski CR, Gullick WJ, Vile RG, Stewart JS (2004) Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer 91:366–373
Hamada A, Kawaguchi T, Nakano M (2002) Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 41:705–718
Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener RA (1986) Treatment of murine L1210 leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149–154
Schwendener RA, Schott H (1992) Treatment of L1210 murine leukemia with liposome - incorporated N4-hexadecyl-1-β-d-arabino-furanosyl-cytosine. Int J Cancer 51:466–469
Schwendener RA, Schott H (2005) Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Meth Enzymol 391:58–70
Horber DH, Schott H, Schwendener RA (1995) Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-d-arabino-furanosylcytosine, a lipophilic derivative of 1-β-d-arabinofuranosylcytosine. Br J Cancer 71:957–962
Horber DH, von Ballmoos P, Schott H, Schwendener RA (1995) Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-β-d-arabinofuranosylcytosine, a new lipophilic derivative of 1-β-d-arabino-furanosylcytosine. Br J Cancer 72:1067–1073
Horber DH, Schott H, Schwendener RA (1995) Cellular pharmacology of N4-hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36:483–492
Schwendener RA, Friedl K, Depenbrock H, Schott H, Hanauske AR (2001) In vitro activity of liposomal N4octadecyl-1-β-d-arabino-furanosylcytosine (NOAC), a new lipophilic derivative of 1-β-d-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Invest New Drugs 19:203–210
Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ (2008) Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 7:84–99
Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ (2001) Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47:251–276
Koller-Lucae SKM, Schott H, Schwendener RA (1997) Pharmacokinetic properties in mice and interactions with human blood in vitro of liposomal N4-octadecyl-1-β-d-arabinofuranosylcytosine (NOAC), a new anticancer drug. J Pharmacol Exp Thera 282:1572–1580
Koller-Lucae SKM, Suter MJ, Rentsch KM, Schott H, Schwendener RA (1999) Metabolism of the new liposomal anticancer drug N4-octadecyl-1-β-d-arabinofuranosylcytosine (NOAC) in mice. Drug Metab Dispos 27:342–350
Koller-Lucae SM, Schott H, Schwendener RA (1999) Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-d-arabinofuranosylcytosine (NOAC) in Daudi lymphoma cells. Br J Cancer 80:1542–1549
Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P, Schott H, Ludwig PS, Eriksson S, Fichtner I, Schwendener RA (2000) Cytotoxicity, cell cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-β-d-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′ → 5′)-N4-octadecyl-1-β-d-ara-C. J Cancer Res Clin Oncol 126:311–319
Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Derighetti M, Schwendener RA (2000) Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Biochem Pharmacol 60:1887–1896
Cattaneo-Pangrazzi RM, Schott H, Schwendener RA (2000) The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate 45:8–18
Marty C, Ballmer-Hofer K, Neri D, Klemenz R, Schott H, Schwendener RA (2002) Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 87:106–112
Takatori S, Kanda H, Takenaka K, Wataya Y, Matsuda A, Fukushima M, Shimamoto Y, Tanaka M, Sasaki T (1999) Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol 44:97–104
Schwendener RA, Gowland P, Horber DH, Zahner R, Schertler A, Schott H (1994) New lipophilic acyl/alkyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Res 24:79–93
Peghini PA, Zahner R, Kuster H, Schott H, Schwendener RA (1998) In vitro inhibition of hepatitis B virus replication and pharmacokinetic properties of new lipophilic dinucleoside phosphate derivatives. Antivir Chem Chemother 9:117–126
Mayer LD, Hope MJ, Cullis PR (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858:161–168
Rentsch KM, Schwendener RA, Schott H, Hänseler E (1997) Pharmacokinetics of N4-octadecyl-1-β-d-arabinofuranosylcytosine (NOAC) in plasma and whole blood after intravenous and oral application in mice. J Pharm Pharmacol 49:1076–1081
Schwendener RA, Asanger M, Weder HG (1981) The preparation of large bilayer liposomes: controlled removal of n-alkyl-glucoside detergents from lipid/detergent micelles. Biochem Biophys Res Commun 100:1055–1062
Schwendener RA (1986) The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer. Cancer Drug Deliv 3:123–129
Allen TM (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215–220
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Schwendener, R.A., Schott, H. (2017). Liposome Formulations of Hydrophobic Drugs. In: D'Souza, G. (eds) Liposomes. Methods in Molecular Biology, vol 1522. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6591-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6591-5_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6589-2
Online ISBN: 978-1-4939-6591-5
eBook Packages: Springer Protocols